Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CAPR

Capricor Therapeutics Inc

7.43

Aug 19 • 10:42 AM ET +0.35 (4.94%)

Healthcare Biotechnology USA Small NASD

Peers: INCY KYMR BMRN CRNX MDGL RYTM KRYS AXSM VKTX NBIX

| Held by: XBI IWM VTI FESM IWO VXF VTWO LABU FSCC VHT

Scroll to Statements

Index	RUT
Market Cap	431.97M
Enterprise Value	285.09M
Income	-129.42M
Sales	0.00M
Book/sh	4.24
Cash/sh	4.09
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	231
IPO	Jun 20, 2002

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.75
P/C	1.82
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.35
Current Ratio	7.35
Debt/Eq	0.37
LT Debt/Eq	0.36
Option/Short	Yes / Yes

EPS (ttm)	-2.45
EPS next Y	-1.49
EPS next Q	-0.12
EPS this Y	33.63%
EPS next Y	0.60%
EPS next 5Y	50.75%
EPS past 3/5Y	-24.12% -20.84%
Sales past 3/5Y	- -
EPS Y/Y TTM	-49.28%
Sales Y/Y TTM	-100.00%
EPS Q/Q	-24.04%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-18.87% -

Insider Own	9.67%
Insider Trans	-4.62%
Inst Own	69.94%
Inst Trans	10.53%
ROA	-51.53%
ROE	-73.70%
ROIC	-38.54%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	2.20%
SMA50	-57.43%
SMA200	-67.97%
Trades

Shs Outstand	58.11M
Shs Float	52.52M
Short Float	30.44%
Short Ratio	3.47
Short Interest	15.98M
52W High	40.37 -81.60%
52W Low	2.96 151.01%
Volatility	17.94% 15.81%
ATR (14)	1.47
RSI (14)	37.22
Beta	0.63
Rel Volume	2.63
Avg Volume	4.61M
Volume	2,732,590

Perf Week	77.33%
Perf Month	-62.46%
Perf Quarter	-72.40%
Perf Half Y	-70.90%
Perf YTD	-74.26%
Perf Year	-3.13%
Perf 3Y	7.53%
Perf 5Y	95.53%
Perf 10Y	-79.70%
Recom	2.80
Target Price	26.12
Prev Close	7.08
Price	7.43
Change %	4.94%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-14-26	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$28
Jul-30-26	Downgrade	Piper Sandler	Overweight → Neutral	$2
Jul-30-26	Downgrade	Oppenheimer	Outperform → Perform
Jul-30-26	Downgrade	Maxim Group	Buy → Hold
Jul-30-26	Downgrade	Ladenburg Thalmann	Buy → Neutral
Jul-30-26	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-30-26	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$3.50
Jul-28-26	Downgrade	Alliance Global Partners	Buy → Neutral	$7
Jul-27-26	Downgrade	Roth Capital	Buy → Neutral	$7
Jul-27-26	Downgrade	B. Riley Securities	Buy → Neutral	$10
Jun-30-25	Initiated	Alliance Global Partners	Buy	$20
Jun-26-25	Initiated	B. Riley Securities	Buy	$21
May-20-25	Initiated	Roth Capital	Buy	$31
Oct-21-24	Initiated	Piper Sandler	Overweight	$35
May-17-24	Initiated	Oppenheimer	Outperform	$14
Jan-05-24	Initiated	Cantor Fitzgerald	Overweight	$8
Oct-26-22	Initiated	Ladenburg Thalmann	Buy	$15
Dec-26-18	Downgrade	Maxim Group	Buy → Hold
Jan-26-18	Reiterated	H.C. Wainwright	Buy	$6.50 → $8.60
Sep-15-17	Reiterated	H.C. Wainwright	Buy	$2.15 → $6.50

Show Previous Ratings

Aug-17-26 01:17AM	Goldman Sachs Builds $75M Bet Across CAPR, SLS And IBRX As Major Catalysts Loom (Stocktwits) +12.03%
Aug-15-26 08:30AM	Capricor Therapeutics, Inc. Q2 2026 Earnings Call Summary (Moby)
Aug-14-26 09:15AM	Kaplan Fox Encourages Capricor Therapeutics, Inc. (CAPR) Investors with Losses to Contact the Firm Before September 28, 2026 (Newsfile) +57.96%
06:18AM	CAPR Stock Explodes Premarket: Cantor Flips Bullish, Sees 278% Upside On Deramiocel FDA Path (Stocktwits)
05:28AM	Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers (BioPharma Dive)
01:03AM	Loading…
01:03AM	Capricor Therapeutics Inc (CAPR) (Q2 2026) Earnings Call Highlights: Navigating FDA Setback and ... (GuruFocus.com)
Aug-13-26 07:32PM	CAPR Stock Surges 67% After-Hours Is There Still A Path Forward For Deramiocel? (Stocktwits)
05:00PM	Capricor: Q2 Earnings Snapshot (Associated Press)
04:05PM	Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
04:12AM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR (PR Newswire)
Aug-11-26 07:07AM	CAPR Investor Announcement: Capricor Therapeutics Sued on behalf of Investors to Recover Losses after Clinical Data Leads to 64% Stock Drop (PR Newswire)
Aug-10-26 08:30AM	Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13 (GlobeNewswire) -5.87%
Aug-06-26 04:09PM	Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (CAPR) Who Suffered Losses to Contact the Firm Before September 28, 2026 (Newsfile) +6.36%
Aug-05-26 04:08PM	Kaplan Fox Urges Investors of Capricor Therapeutics, Inc. (CAPR) with Significant Losses to Seek a Leadership Role Before September 28, 2026 (Newsfile) -5.76%
Aug-03-26 05:26PM	MRNA, LNTH, BMY, CAPR, RARE Stocks In Focus These FDA Decisions Could Shape August Trading (Stocktwits) +9.09%
07:30AM	Loading…
07:30AM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights CAPR (Business Wire)
Jul-31-26 01:42PM	CAPR Stock On Track For Worst Week Ever After Regulatory Setback For DMD Therapy (Stocktwits) -8.11%
Jul-30-26 11:32PM	Why did CAPR, LKQ, PSKY Stocks Plunge To 52-Week Lows Today? (Stocktwits) -36.23%
10:55AM	Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel (Business Wire)
09:38AM	Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls (The Fly)
09:30AM	Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel (GlobeNewswire)
07:58AM	Capricors FDA Fate Divides Wall Street And Investors: One Analyst Sees A $2 Stock But Retail Holds Out Hope (Stocktwits)
Jul-29-26 11:07PM	CAPR Stock Eyes Worst Week Ever After FDA Panel Blow To Deramiocel Retail Bulls Still See A Path To Approval (Stocktwits)
06:25PM	FDA Advisory Panel Votes Against Capricor Therapy (The Wall Street Journal)
04:24PM	Capricor Faces Make-Or-Break FDA Panel For Duchenne Cell Therapy Experts And Investors Weigh In (Stocktwits)
12:20PM	Capricors DMD Therapy Gets Lancet Backing Ahead Of August FDA Showdown CEO Says Publication Reinforce Our Confidence For Approval (Stocktwits)
10:05AM	The Lancet Publishes HOPE-3 Data for Capricor Therapeutics' Deramiocel in Duchenne Muscular Dystrophy (GlobeNewswire)
Jul-28-26 12:07PM	This Analyst Slashed CAPR Stocks Target By 86% But, Retail Bulls Say Setup Offers An Attractive Risk-Reward (Stocktwits) -6.08%
Jul-27-26 10:38PM	CAPR Stock Eyes Worst Month In 9 Years On FDA Doubts Pharma Bro Shkreli Piles On, But Retail Turns More Bullish Than Ever (Stocktwits) -64.49%
03:42PM	CAPR Stock On Track For Worst Day Ever Analysts Divided On Deramiocels Approval Probability After FDA Documents Paint Ugly Picture (Stocktwits)
11:39AM	Loading…
11:39AM	Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review CAPR Stock Plummets After Agency Released Briefing Document (Stocktwits)
11:00AM	Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel (GlobeNewswire)
10:50AM	Capricor Therapeutics shares tumble after FDA reviewers raise concerns over Duchenne therapy (Proactive)
09:48AM	CAPR Stock Is Crashing Today FDA Briefing Casts Doubt On Duchenne Cell Therapy Before Key Vote (Stocktwits)
09:43AM	Capricor Therapeutics shares plunge after FDA releases briefing documents (InvestorsHub)
07:00AM	FDA scientists question Capricor data; Legend CEO steps down (BioPharma Dive)
Jul-24-26 08:30PM	FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions (Stocktwits)
Jul-23-26 08:09PM	CAPR Stock On Track To Clock Weekly Gains Ahead Of Critical FDA Panel Retail Deems It A Binary Event (Stocktwits)
Jul-22-26 06:52AM	CAPR Stock Eyes 1st Weekly Gain In 5 Weeks: Capricors DMD Therapy Faces FDA Panel Review Next Week, Retail Sees 'Excellent Opportunity' (Stocktwits)
Jun-30-26 12:15AM	CAPR Stock Hits Over 4-Month Low: Capricor Execs Cash In $1.5M As FDA Sets Stage For DMD Drug Review (Stocktwits)
Jun-26-26 11:58AM	Capricors Positive 5-Year Data For DMD Treatment Comes With A Regulatory Catch CAPR Stock Slides 11% (Stocktwits) -13.03%
10:02AM	Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
09:05AM	Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference (GlobeNewswire)
Jun-17-26 10:24AM	All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement CAPR Stock Jumps 6% (Stocktwits) +7.29%
Jun-08-26 09:25AM	Capricor Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-13-26 01:02AM	Capricor Therapeutics Inc (CAPR) Q1 2026 Earnings Call Highlights: Strong Cash Position Amid ... (GuruFocus.com)
May-12-26 04:21PM	Capricor: Q1 Earnings Snapshot (Associated Press)
04:05PM	Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-11-26 06:00AM	Inhibrx delivers differentiated cancer drug data; Fractyl starts diabetes gene therapy trial (BioPharma Dive) +5.00%
May-04-26 04:05PM	Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 (GlobeNewswire) +8.38%
Apr-22-26 09:00AM	Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting (GlobeNewswire)
Mar-25-26 07:30AM	Caprock Intersects 38.48 g/t Au over 1.6m Included Within a Broader Interval of 2.84 g/t over 23.2m at Destiny (TMX Newsfile)
Mar-23-26 10:50AM	Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp. (TMX Newsfile)
Mar-12-26 11:07PM	Capricor Therapeutics Inc (CAPR) Q4 2025 Earnings Call Highlights: FDA Milestones and Financial ... (GuruFocus.com) -8.74%
04:27PM	Capricor: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
09:00AM	Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy (GlobeNewswire)
Mar-10-26 10:47AM	Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review (Benzinga) +9.04%
09:25AM	Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA (GlobeNewswire)
07:00AM	Xenon hits a home run in epilepsy; FDA restarts review of Duchenne cell therapy (BioPharma Dive)
Mar-09-26 01:32PM	What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? (Benzinga) +9.78%
01:15PM	Biotech Stocks Rally on Departure of Polarizing FDA Official (The Wall Street Journal)
08:30AM	Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12 (GlobeNewswire)
Mar-03-26 05:30AM	MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines (The Wall Street Journal)
Feb-24-26 09:00AM	Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference (GlobeNewswire)
Jan-21-26 10:49AM	CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February (Zacks)
Jan-20-26 09:15AM	Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data (GlobeNewswire)
Jan-09-26 06:01AM	Here's Why This Biotechnology Skyrocketed by 439% in December (Motley Fool) -6.69%
Dec-18-25 01:14PM	Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory (Insider Monkey)
Dec-16-25 04:05PM	Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy (GlobeNewswire)
Dec-05-25 10:34AM	CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know (Zacks) +5.87%
06:15AM	Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock (GlobeNewswire)
Dec-04-25 04:01PM	Capricor Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) -15.22%
Dec-03-25 01:03PM	Capricor Skyrockets 535% After Getting Vindication In Muscular Dystrophy (Investor's Business Daily) +371.07%
10:36AM	Biotech Stock Up Over 400% After Late-Stage Breakthrough (Schaeffer's Research)
07:20AM	Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy (GlobeNewswire)
06:10AM	Capricor soars on positive results for Duchenne cell therapy (BioPharma Dive)
Nov-24-25 09:00AM	Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025 (GlobeNewswire) -19.30%
Nov-11-25 12:00AM	Capricor Therapeutics Inc (CAPR) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com) +11.51%
Nov-10-25 04:50PM	Capricor: Q3 Earnings Snapshot (Associated Press Finance) -6.24%
04:01PM	Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-25 06:05PM	CeriBell, Inc. (CBLL) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-03-25 09:15AM	Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel (GlobeNewswire) -6.76%
Oct-31-25 09:15AM	Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10 (GlobeNewswire)
Oct-30-25 09:23AM	Capricor (CAPR) Moves 12.0% Higher: Will This Strength Last? (Zacks) -10.26%
Sep-26-25 06:45AM	Capricor (CAPR) Surges 5.3%: Is This an Indication of Further Gains? (Zacks) +8.74%
Sep-25-25 07:15AM	Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting (GlobeNewswire) +5.33%
06:50AM	Capricor readies revised FDA pitch for Duchenne cell therapy (BioPharma Dive)
Sep-10-25 07:43AM	Capricor refutes FDAs DMD deramiocel rejection in public statement (Pharmaceutical Technology)
Sep-09-25 09:20AM	Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel (GlobeNewswire)
Sep-02-25 03:40AM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR (PR Newswire)
Aug-28-25 04:21PM	Investors in Capricor Therapeutics, Inc. (CAPR): Protect Your Rights - Contact Levi & Korsinsky Before September 15, 2025 (Newsfile)
Aug-25-25 09:22AM	Did You Lose Money on Capricor Therapeutics, Inc. (CAPR)? Levi & Korsinsky Urges Investors to Act Before September 15, 2025 (Newsfile) -7.04%
Aug-21-25 04:20PM	Shareholders of Capricor Therapeutics, Inc. (CAPR): Protect Your Rights Before September 15, 2025 - Contact Levi & Korsinsky (Newsfile)
Aug-18-25 09:00AM	Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine (GlobeNewswire)
08:28AM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR (PR Newswire)
Aug-15-25 09:15AM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CAPR (PR Newswire)
Aug-14-25 04:26PM	Capricor Therapeutics, Inc. (CAPR) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before September 15, 2025 (Newsfile) -6.27%
Aug-12-25 09:30AM	Capricor Therapeutics Inc (CAPR) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
03:05AM	Capricor Therapeutics Inc (CAPR) Q2 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy ("DMD"), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

M.D.Dr. Frank Isaac Litvack FACC

Co-FounderDr. Linda Marban Ph.D.

CFO & Corporate TreasurerMr. Anthony J. Bergmann M.B.A.

J.D.Ms. Karen G. Krasney Esq.

Chief Operating & Science OfficerDr. Kristi A. H. Elliott Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Krasney Karen	EVP, GENERAL COUNSEL	Jun 25 '26	Option Exercise	3.18	24,100	76,638	54,647	Jun 29 09:30 PM
Krasney Karen	EVP, GENERAL COUNSEL	Jun 25 '26	Sale	30.38	24,100	732,158	30,547	Jun 29 09:30 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Jun 25 '26	Option Exercise	3.18	24,100	76,638	35,323	Jun 29 09:30 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Jun 25 '26	Sale	30.38	24,100	732,158	11,223	Jun 29 09:30 PM
Krasney Karen	EVP, GENERAL COUNSEL	Jun 22 '26	Option Exercise	3.18	500	1,590	31,047	Jun 24 08:00 PM
Krasney Karen	EVP, GENERAL COUNSEL	Jun 24 '26	Option Exercise	3.18	400	1,272	30,947	Jun 24 08:00 PM
Krasney Karen	EVP, GENERAL COUNSEL	Jun 22 '26	Sale	30.00	500	15,000	30,547	Jun 24 08:00 PM
Krasney Karen	EVP, GENERAL COUNSEL	Jun 24 '26	Sale	30.00	400	12,000	30,547	Jun 24 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Jun 22 '26	Option Exercise	3.18	500	1,590	11,723	Jun 24 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Jun 24 '26	Option Exercise	3.18	400	1,272	11,623	Jun 24 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Jun 22 '26	Sale	30.00	500	15,000	11,223	Jun 24 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Jun 24 '26	Sale	30.00	400	12,000	11,223	Jun 24 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	May 18 '26	Option Exercise	1.39	3,000	4,170	11,223	May 19 04:15 PM
Musket David B	Director	May 19 '26	Proposed Sale	27.00	88,788	2,397,256		May 19 11:40 AM
Litvack Frank	Director	May 13 '26	Option Exercise	1.39	3,937	5,472	133,776	May 14 05:00 PM
Krasney Karen	EVP, GENERAL COUNSEL	May 01 '26	Option Exercise	3.18	25,000	79,500	55,547	May 04 04:30 PM
Krasney Karen	EVP, GENERAL COUNSEL	May 01 '26	Sale	31.70	25,000	792,548	30,547	May 04 04:30 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	May 01 '26	Option Exercise	3.18	25,000	79,500	33,223	May 04 04:30 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	May 01 '26	Sale	31.70	25,000	792,540	8,223	May 04 04:30 PM
Sabar Karimah Es	Director	Apr 02 '26	Option Exercise	3.18	7,529	23,942	7,529	Apr 03 05:00 PM
Sabar Karimah Es	Director	Apr 02 '26	Sale	32.00	7,529	240,928	0	Apr 03 05:00 PM
Karimah Es Sabar	Director	Apr 02 '26	Proposed Sale	30.12	7,529	226,773		Apr 02 04:24 PM
Krasney Karen	EVP, GENERAL COUNSEL	Mar 31 '26	Option Exercise	3.61	25,000	90,293	55,547	Apr 01 08:00 PM
Krasney Karen	EVP, GENERAL COUNSEL	Mar 31 '26	Sale	30.12	25,000	752,935	30,547	Apr 01 08:00 PM
Sabar Karimah Es	Director	Mar 31 '26	Option Exercise	4.86	61,265	297,748	61,265	Apr 01 08:00 PM
Sabar Karimah Es	Director	Apr 01 '26	Option Exercise	4.86	53,735	261,152	53,735	Apr 01 08:00 PM
Sabar Karimah Es	Director	Mar 31 '26	Sale	30.17	61,265	1,848,243	0	Apr 01 08:00 PM
Sabar Karimah Es	Director	Apr 01 '26	Sale	31.03	53,735	1,667,225	0	Apr 01 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Mar 31 '26	Option Exercise	3.18	25,000	79,500	33,223	Apr 01 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Mar 31 '26	Sale	30.13	25,000	753,152	8,223	Apr 01 08:00 PM
Karen Krasney	Officer	Mar 31 '26	Proposed Sale	27.77	75,000	2,082,750		Mar 31 04:23 PM
ANTHONY BERGMANN	Officer	Mar 31 '26	Proposed Sale	27.77	75,000	2,082,750		Mar 31 04:23 PM
Karimah Es Sabar	Director	Mar 31 '26	Proposed Sale	27.77	115,000	3,193,550		Mar 31 04:22 PM
Krasney Karen	EVP, GENERAL COUNSEL	Dec 30 '25	Option Exercise	1.39	2,500	3,475	30,547	Mar 27 07:15 PM
DUNBAR GEORGE W JR	Director	Dec 19 '25	Option Exercise	1.39	3,000	4,170	14,306	Dec 23 02:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CAPR

Capricor Therapeutics Inc

Upgrade your Finviz experience